Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial

File(s)

Ndiaye BP et al..pdf (465.67 KB)

Published version

Show more

Author(s)

Ndiaye, BP

Thienemann, F

Ota, M

Landry, BS

Camara, M

more

Type

Journal Article

Date Issued

2015-02-26

Date Acceptance

2015-02-26

Citation

The Lancet Respiratory Medicine, 2015, 3 (3), pp.190-200

URI

http://hdl.handle.net/10044/1/23868

DOI

https://www.dx.doi.org/10.1016/S2213-2600(15)00037-5

ISSN

2213-2600

Publisher

Elsevier

Start Page

190

End Page

200

Journal / Book Title

The Lancet Respiratory Medicine

Volume

3

Issue

3

Copyright Statement

© 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

License URL

Attribution-NonCommercial-NoDerivatives 4.0 International

Subjects

Science & Technology

Life Sciences & Biomedicine

Respiratory System

MYCOBACTERIUM-TUBERCULOSIS

PROTECTIVE EFFICACY

VIRUS ANKARA

SOUTH-AFRICA

DOUBLE-BLIND

BCG VACCINE

METAANALYSIS

PREVENTION

MENINGITIS

AG85A

Publication Status

Published